Functions · Market access & HEOR

Market Access & HEOR

Build the evidence base payers and HTA bodies will reference: endpoints, comparators, outcome sets and where trials concentrate.

14ranked use cases
#15highest overall rank: Endpoint benchmarking
1 clickfrom recipe to a board with the right charts
Lead chart, on real data

What this team sees first.

Where trials recruit signals where evidence and payer attention build. In atopic dermatitis, China hosts 28 of 48 recruiting industry trials.

Every use case below opens with its signature chart and a recommended set of supporting views, chosen from 91 chart types.

Built for: HEOR Lead, Value & Access Strategy Lead, HTA Submission Lead, HEOR, Market Access.

Tile map · where trials recruitReal data

China hosts 28 of 48 recruiting industry atopic dermatitis trials

ClinicalTrials.gov API, pulled 16 Oct 2026: recruiting, interventional, industry lead sponsor, Phase 2–3 atopic dermatitis (n = 48). A multinational trial counts in every country with a site. Tiles are placed roughly by geography.

The 14 questions

Ranked by stakes, centrality, reach, frequency and data fit.

Each use case ships with an executive brief, a detailed dossier and a recipe that builds the board in one click.

  • HE-01
    #15

    Endpoint benchmarking

    Understand which endpoints are used across the indication to align with payer expectations.

    For: HEOR Lead
    Paired comparison / dumbbell chartBar / column chartGrouped bar
  • HE-11N
    #16

    HTA decision precedent & comparator intelligence

    See what HTA bodies have accepted, rejected, and required — comparators, endpoints and evidence — in the indication.

    For: Value & Access Strategy Lead
    BullseyePaired comparison / dumbbell chartBar / column chart
  • HE-02
    #23

    HTA submission preparation

    Compile the full Phase 3 evidence base an HTA body will reference.

    For: HTA Submission Lead
    Composition / share-of-inventory chartKPI / metric snapshot panelPaired comparison / dumbbell chart
  • HE-03
    #24

    Comparator identification

    Identify the standard-of-care comparators used in completed trials for payer dossiers.

    For: HEOR / Market Access Manager
    Paired comparison / dumbbell chartBar / column chartGrouped bar
  • HE-12N
    #25

    Core-outcome-set & COA alignment

    Benchmark planned endpoints against accepted core outcome sets, regulatory COAs and patient-reported standards.

    For: HEOR / Clinical Development Lead
    Paired comparison / dumbbell chartBar / column chartGrouped bar
  • HE-13N
    #37

    Biosimilar / generic entry forecasting

    Forecast when biosimilars or generics can enter, from exclusivity status and competitor development activity.

    For: Market Access / Lifecycle Lead
    TimelineFan chartPaired comparison / dumbbell chart
  • HE-04
    #54

    Country-level submission prioritization

    See where trials in your indication have concentrated to identify payer-ready markets.

    For: Global Market Access Lead
    Choropleth mapTimelineQuadrant map
  • HE-05
    #55

    Orphan drug designation support

    Document the limited trial and patient landscape in a rare disease to support orphan status.

    For: Regulatory / Market Access Lead
    BullseyePaired comparison / dumbbell chartBar / column chart
  • HE-06
    #56

    Value dossier differentiation

    Identify differentiating data points your product can claim in AMCP or HTA dossiers.

    For: Value & Access Strategy Lead
    Value curve / strategy canvasPaired comparison / dumbbell chartKPI / metric snapshot panel
  • HE-07
    #65

    Indirect treatment comparison (ITC) mapping

    Build the network of evidence needed for a network meta-analysis via shared comparator arms.

    For: HEOR Statistician / Evidence Synthesis Lead
    Combo chartPaired comparison / dumbbell chartBar / column chart
  • HE-08
    #66

    Patient population size estimation

    Use enrollment data to support epidemiological assumptions in cost-effectiveness models.

    For: HEOR Modeler
    KPI / metric snapshot panelPaired comparison / dumbbell chartBar / column chart
  • HE-14N
    #67

    Patient-centred (PRO) outcome strategy

    Build a patient-reported and patient-centred outcome strategy aligned to recognised standards and HTA expectations.

    For: HEOR / Patient-Centred Outcomes Lead
    BullseyePaired comparison / dumbbell chartBar / column chart
  • HE-09
    #80

    Payer evidence planning

    Identify the health-outcomes and economic evidence already being generated to avoid duplication.

    For: Market Access Evidence Lead
    Paired comparison / dumbbell chartBar / column chartGrouped bar
  • HE-10
    #81

    Budget impact model input

    Estimate current trial patient volume to inform budget-impact model assumptions for payers.

    For: Market Access Modeler
    KPI / metric snapshot panelPaired comparison / dumbbell chartBar / column chart
Try it

Ask the registry a market access & heor question.

Ask the registryAI-assisted

AI reads your question into filters; every number comes straight from the ClinicalTrials.gov API. Don't enter personal or confidential information.

Bring one market access & heor question to a pilot.

Eight weeks, one programme, success criteria agreed up front.

Plan a pilot